PulseFlow is an innovative technology company that provides precise and personalized diagnosis and treatment of cardiovascular diseases based on medical big data, computational simulation technology and artificial intelligence algorithms. The core R&D team consists of PhDs and masters graduates from MIT, Imperial College, and other world-class universities. The team has accumulated a wealth of experience in computational simulation, artificial intelligence, and medical imaging, and has published hundreds of academic papers, and the core team not only understands the technology, but also has a deep understanding of the clinic.
Up to now, Pulseflow has 11 products that have obtained China NMPA, U.S. FDA, and European CE registration certificates. Of these, 7 products have received China NMPA registration, 3 products have received European CE registration, and 1 product has received U.S. FDA registration.
AneuFlow, a self-developed intracranial aneurysm diagnostic system, is the first hemodynamic-based intracranial aneurysm evaluation system in China. At the same time, AneuFlow's non-invasive coronary function assessment products, AccuCT based on coronary CTA and AccuAngio based on coronary angiography, were simultaneously granted marketing registration certificates, making AneuFlow the first company in China to have coronary function assessment products based on both coronary CTA and coronary angiography. This is another milestone for the company after obtaining CE marking for these two products simultaneously.
Subsequently, on May 28, 2021, Pulseflow held a launch event for its cardiovascular and cerebrovascular functional assessment platform during the 15th Oriental Cardiology Conference (OCC 2021), with the theme of "Heart, Brain and Function First". During the 15th Oriental Cardiology Conference (OCC 2021), the launch of the cardiovascular functional assessment platform was held. At the conference, AneuFlow launched three approved innovative products for functional assessment of cardiovascular and cerebrovascular diseases - AneuFlow, AccuCT and AccuAngio. Cardiovascular experts Prof. Ge Junbo, Prof. Wang Jian'an and Prof. Shen Lei, as well as cerebrovascular disease experts Prof. Liu Jianmin and Prof. Jiang Weijian were present at the launch event*** to witness the launch of AneuFlow's products.
While PulseFlow has obtained registration certificates for its products to gain market access, the company is also accelerating the commercialization of its products. Pulseflow Technologies has been building its marketing team since early 2021 to actively expand its market. Currently, the company's marketing team*** consists of more than 40 people, covering two areas of cardiovascular and cerebrovascular intelligent diagnosis and treatment, covering more than 30 provinces, autonomous regions and municipalities, as well as Europe and the United States, two major overseas regions. Our products have landed in more than 200 comprehensive and cardiovascular specialty hospitals.
In terms of cardiovascular products, the company has established a set of strategic cooperation models with a series of head hospitals, including Shanghai Zhongshan Hospital, the Second Affiliated Hospital of Zhejiang University School of Medicine, Beijing Anzhen Hospital, Beijing 301 Hospital, including academic promotion, product development and commercial landing. In addition, with the industry's leading cerebrovascular products, Pulseflow Technology is also actively promoting new non-invasive diagnostic and treatment concepts and methods, joining hands with national cerebrovascular diagnostic and treatment centers such as Shanghai Changhai Hospital, Beijing Tiantan Hospital, Shanghai Huashan Hospital, etc., to realize the research and development of products for the whole process of cerebral strokes and their promotion.
Meanwhile, the company is also launching and practicing new business models. By establishing a complete commercial closed loop of patients-entity hospitals-internet hospitals-products service enterprises together with internet hospitals, the company innovatively realizes the commercial landing of its products as permitted by laws and regulations. At present, this model has promoted the company's products in more than 50 hospitals to achieve commercialization landing, charging more than a thousand cases.
With the popularization and deepening of the concept of intelligent diagnosis and treatment, as well as the huge market volume of cardiovascular and cerebrovascular diagnosis and treatment, coupled with the traditional model with the new business model, the company's commercial sales in the field of cardiovascular and cerebrovascular intelligent diagnosis and treatment in the next few years is expected to realize the spurt of growth.
In addition, pulse flow technology and CCI Innovation Institute set up the "China Cardiovascular Doctors Innovation Club Hemodynamics Joint Laboratory" on October 10 officially opened. The lab aims to strengthen hemodynamic research in the pan-vascular field, and in the future will open a series of joint experiments in hemodynamic monitoring, guidance, evaluation of endovascular treatment strategies and other basic research and innovation, and utilize hemodynamics in the pan-vascular field of the wide range of applications, to promote the continuous medical-industrial integration and innovation transformation.
At the same time, in order to establish its brand advantage, ArteryFlow has also created its own academic and professional education brand "ArteryFlow Academy", which includes two parts: offline "ArteryFlow Pillar" and online "ArteryFlow Online". ArteryFlow Academy" consists of two parts: offline "ArteryFlow Pillar" and online "ArteryFlow Online". The goal of "ArteryFlow Academy" is to promote cardiovascular and cerebrovascular intelligent diagnosis and treatment technology, and to build up ArteryFlow's own "academic circle" and "fan group" by organizing regular exchanges and sharing of the latest advances in cardiovascular and cerebrovascular intelligent diagnosis and treatment, as well as cases and experience of use among doctors. This year, Pulseflow Academy*** has organized nearly 20 events, which has greatly increased customer stickiness.
PulseFlow has also been actively involved in various top academic conferences at home and abroad, utilizing its wealth of domestic and international experts to promote the company and introduce corresponding disease solutions. This year, PulseFlow has hosted more than 20 nationwide academic conferences on cardiovascular and cerebrovascular intelligent diagnosis and treatment, and participated in more than 40 regional academic conferences, which have been widely recognized and favored by experts in various fields. Attachment